Drugs Controller General of India
The Drugs Controller General of India (DCGI) has said that the blood center across the nation can charge only processing costs as blood is not for sale. The DCGI has banned all charges except supply and processing costs on blood units.
In reference with the 62nd meeting of the Drugs Consultative Committee held on September 26, 2023, the DCGI has highlighted to address the issue of overcharging for blood, that blood is not meant for sale but for supply, and consequently, only processing costs should be levied by blood centres.
In an official communication to all states and UTs Drug Controllers Cum Licensing Authority on December 26, the DCGI stated, “It was recommended with respect to agenda No. 18 of ATR point 3, for overcharging of blood, it was opined that blood is not for sale, it is only for supply and only processing cost may be charged by the blood centre”=.
The blood centres have been now authorised to charge only processing fees for blood or blood components. These fees have been stipulated to range between Rs 250 to Rs 1,550 for blood or blood components. The DCGI has urged states and Union Territory drug controllers to ensure strict adherence to these guidelines by all blood centres within their jurisdiction.
Following a statement from Tata Memorial Centre, Dr. Abhishek Shankar, a senior oncologist from AIIMS…
Reacting to Navjot Singh Sidhu’s claim on wife’s cancer treatment and outcome, a group of oncologists…
The Union health ministry entered into a tripartite Memorandum of Understanding (MoU) with Banaras Hindu…
A recent claim by Punjabi leader and former cricketer Navjot Singh Sidhu regarding his wife…
Pancreatic cancer has been on a steady rise over the last 5-10 years can be…
Amid the worsening air pollution in Delhi and NCR region, the Indian Chest Society on…